Terrestrial Bio
Cambridge
About Terrestrial Bio
Vaxess Technologies is developing the MIMIX™ sustained release patch technology, the easiest and most effective way to administer vaccines and therapeutics. For vaccines, the controlled release simulates the pace of a natural infection, helping the body produce a slow, strong, and enduring ramp-up of immune response, ultimately boosting a vaccine’s effectiveness. Engineered for stability, Vaxess’s patch does not require refrigeration and can be shipped to and applied in low resource settings.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $180.9M
- Funding stage: Late Stage Venture
- Last round: Series C (Mar 2026)
- Website: vaxess.com
- Phone: 614-507-9586
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/terrestrial-bio-24875 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.